Expression of gonadotropin releasing hormone receptor in breast cancer tissue and its clinical significance

doi:10.3877/cma.j.issn.1674-0807.2017.02.003

Abstract

Abstract:

Objective

To investigate the expression of gonadotropin releasing hormone receptor(GnRH-R) in breast cancer tissue and its correlation with patients' clinicopathological characteristics.

Methods

We collected surgically resected specimens from 104 cases of invasive ductal breast cancer in the Affiliated Hospital of Jiangnan University from December 2010 to January 2008 for a retrospective study. The expression of GnRH-R in breast cancer tissue was detected by immunohistochemical SP method. The correlation between GnRH-R expression and patients' clinicopathological characteristics was analyzed using χ² test.

Results

The positive rate of GnRH-R in invasive breast cancer tissue was 66.3% (69/104). With regards to different molecular subgroups, the positive rate of GnRH-R was 5/11 in luminal A subtype,61.4%(27/44)in luminal B subtype, 8/16 in HER-2 overexpression subtype and 87.9%(29/33)in triple negative subtype,indicating a significant difference(χ²=11.407,P＜0.050). The pairwise comparison showed that the positive expression rate of GnRH-R in triple negative subtype was significantly higher than that in luminal A subtype(χ²= 8.455,P＜0.008) or HER-2 overexpression subtype(χ²= 8.361,P＜0.008) respectively. The positive rates of GnRH-R in breast cancer tissues presented no significant difference in patients with different ages,histological grade, lymph node metastasis and clinical stages (χ²=0.506,P=0.477; χ²=0.007,P=0.936;χ²=2.158,P=0.340; χ² =0.007,P=0.936).

Conclusion

GnRH-R is highly expressed in triple negative breast cancer tissue, which may provide references for the treatment of triple negative breast cancer.

Key words: Breast neoplasms, Molecular typing, Receptors, GnRH

Ling Chen, Jing He, Dong Meng, Chunlei Sun, Weifeng Shi, Xiaowei Qi, Linfang Jin, Wenhuan Xu, Shifu Zhou. Expression of gonadotropin releasing hormone receptor in breast cancer tissue and its clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2017, 11(02): 74-77.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2017.02.003

https://zhrxbzz.cma-cmc.com.cn/EN/Y2017/V11/I02/74

Figures/Tables 2

References 15

[1]	Cheung LW, Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues [J]. FEBS J, 2008, 275(22):5479-5495.
[2]	Aguilar-Rojas A, Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (review) [J]. Oncol Rep,2009,22(5):981-990.
[3]	Limonta P, Montagnani Marelli M, Mai S, et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies[J].Endocr Rev,2012,33(5):784-811.
[4]	李敏,吴小华,徐翠清,等. GnRHⅠ,GnRHⅡ及其受体在人卵巢恶性上皮性肿瘤细胞中的表达及意义[J]. 第四军医大学学报,2008,29(24):2281-2283.
[5]	Goldhirsch A,Winer EP,Coates AS,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol,2013,24(9):2206-2223.
[6]	DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women[J]. CA Cancer J Clin,2016,66(1):31-42.
[7]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[8]	Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs[J]. Annu Rev Med,1994,45:391-405.
[9]	Schubert A, Hawighorst T, Emons G, et al. Agonists and antagonists of GnRH-Ⅰand -Ⅱreduce metastasis formation by triple-negative human breast cancer cells in vivo[J]. Breast Cancer Res Treat,2011,130(3):783-790.
[10]	Buchholz S, Seitz S, Schally AV, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH)and respond to LHRH antagonist cetrorelix with growth inhibition[J].Int J Oncol,2009,35(4):789-796.
[11]	Grundker C, Fost C, Fister S, et al. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDAMB-231 human breast cancer cells in vitro and in vivo[J]. Breast Cancer Res,2010,12(4): R49.
[12]	Emons G, Muller V, Ortmann O, et al. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells[J]. J Steroid Biochem Mol Biol,1998,65(1-6):199-206.
[13]	Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med,2015,372(10):923-932.
[14]	Schally AV,Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors [J]. Trends Endocrinol Metab, 2004, 15(7):300-310.
[15]	Harrison GS, Wierman ME, Nett TM, et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells[J]. Endocr Relat Cancer,2004,11(4):725-748.

Please choose a citation manager

Content to export